These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
305 related articles for article (PubMed ID: 24858397)
1. Folate and TAT peptide co-modified liposomes exhibit receptor-dependent highly efficient intracellular transport of payload in vitro and in vivo. Zhu Y; Cheng L; Cheng L; Huang F; Hu Q; Li L; Tian C; Wei L; Chen D Pharm Res; 2014 Dec; 31(12):3289-303. PubMed ID: 24858397 [TBL] [Abstract][Full Text] [Related]
2. Antitumor effect of folate-targeted liposomal doxorubicin in KB tumor-bearing mice after intravenous administration. Riviere K; Huang Z; Jerger K; Macaraeg N; Szoka FC J Drug Target; 2011 Jan; 19(1):14-24. PubMed ID: 20353291 [TBL] [Abstract][Full Text] [Related]
3. A comparative study of folate receptor-targeted doxorubicin delivery systems: dosing regimens and therapeutic index. Scomparin A; Salmaso S; Eldar-Boock A; Ben-Shushan D; Ferber S; Tiram G; Shmeeda H; Landa-Rouben N; Leor J; Caliceti P; Gabizon A; Satchi-Fainaro R J Control Release; 2015 Jun; 208():106-20. PubMed ID: 25869964 [TBL] [Abstract][Full Text] [Related]
4. Paclitaxel-loaded, folic-acid-targeted and TAT-peptide-conjugated polymeric liposomes: in vitro and in vivo evaluation. Zhao P; Wang H; Yu M; Cao S; Zhang F; Chang J; Niu R Pharm Res; 2010 Sep; 27(9):1914-26. PubMed ID: 20582454 [TBL] [Abstract][Full Text] [Related]
5. Synthesis and evaluation of a novel ligand for folate-mediated targeting liposomes. Xiang G; Wu J; Lu Y; Liu Z; Lee RJ Int J Pharm; 2008 May; 356(1-2):29-36. PubMed ID: 18258394 [TBL] [Abstract][Full Text] [Related]
6. Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models. Gabizon A; Tzemach D; Gorin J; Mak L; Amitay Y; Shmeeda H; Zalipsky S Cancer Chemother Pharmacol; 2010 May; 66(1):43-52. PubMed ID: 19779718 [TBL] [Abstract][Full Text] [Related]
7. Conjugates of TAT and folate with DOX-loaded chitosan micelles offer effective intracellular delivery ability. Zhang S; Liu Y; Gan Y; Qiu N; Gu Y; Zhu H Pharm Dev Technol; 2019 Feb; 24(2):253-261. PubMed ID: 29688120 [TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of a folate receptor-targeted immunoglobulin G-doxorubicin conjugate. Yang T; Xu L; Li B; Li W; Ma X; Fan L; Lee RJ; Xu C; Xiang G Int J Nanomedicine; 2017; 12():2505-2515. PubMed ID: 28408821 [TBL] [Abstract][Full Text] [Related]
9. Folate-modified poly(2-ethyl-2-oxazoline) as hydrophilic corona in polymeric micelles for enhanced intracellular doxorubicin delivery. Qiu LY; Yan L; Zhang L; Jin YM; Zhao QH Int J Pharm; 2013 Nov; 456(2):315-24. PubMed ID: 24016742 [TBL] [Abstract][Full Text] [Related]
10. Enhanced Cytotoxicity of Folic Acid-Targeted Liposomes Co-Loaded with C6 Ceramide and Doxorubicin: In Vitro Evaluation on HeLa, A2780-ADR, and H69-AR Cells. Sriraman SK; Pan J; Sarisozen C; Luther E; Torchilin V Mol Pharm; 2016 Feb; 13(2):428-37. PubMed ID: 26702994 [TBL] [Abstract][Full Text] [Related]
11. Folate-modified doxorubicin-loaded nanoparticles for tumor-targeted therapy. Wu G; Wang Z; Bian X; Du X; Wei C Pharm Biol; 2014 Aug; 52(8):978-82. PubMed ID: 25017652 [TBL] [Abstract][Full Text] [Related]
12. Theranostic pH-sensitive nanoparticles for highly efficient targeted delivery of doxorubicin for breast tumor treatment. Pan C; Liu Y; Zhou M; Wang W; Shi M; Xing M; Liao W Int J Nanomedicine; 2018; 13():1119-1137. PubMed ID: 29520140 [TBL] [Abstract][Full Text] [Related]
13. Octreotide-modification enhances the delivery and targeting of doxorubicin-loaded liposomes to somatostatin receptors expressing tumor in vitro and in vivo. Sun M; Wang Y; Shen J; Xiao Y; Su Z; Ping Q Nanotechnology; 2010 Nov; 21(47):475101. PubMed ID: 21030757 [TBL] [Abstract][Full Text] [Related]
14. Increased delivery of doxorubicin into tumor cells using extracellularly activated TAT functionalized liposomes: in vitro and in vivo study. Yuan W; Kuai R; Ran R; Fu L; Yang Y; Qin Y; Liu Y; Tang J; Fu H; Zhang Q; Yuan M; Zhang Z; Gao F; He Q J Biomed Nanotechnol; 2014 Aug; 10(8):1563-73. PubMed ID: 25016656 [TBL] [Abstract][Full Text] [Related]
15. Folate receptor-targeted multimodal polymersomes for delivery of quantum dots and doxorubicin to breast adenocarcinoma: In vitro and in vivo evaluation. Alibolandi M; Abnous K; Sadeghi F; Hosseinkhani H; Ramezani M; Hadizadeh F Int J Pharm; 2016 Mar; 500(1-2):162-78. PubMed ID: 26802496 [TBL] [Abstract][Full Text] [Related]
16. Synergistic targeted delivery of payload into tumor cells by dual-ligand liposomes co-modified with cholesterol anchored transferrin and TAT. Tang J; Zhang L; Liu Y; Zhang Q; Qin Y; Yin Y; Yuan W; Yang Y; Xie Y; Zhang Z; He Q Int J Pharm; 2013 Sep; 454(1):31-40. PubMed ID: 23850793 [TBL] [Abstract][Full Text] [Related]
17. Targeted delivery of Doxorubicin by folic acid-decorated dual functional nanocarrier. Lu J; Zhao W; Huang Y; Liu H; Marquez R; Gibbs RB; Li J; Venkataramanan R; Xu L; Li S; Li S Mol Pharm; 2014 Nov; 11(11):4164-78. PubMed ID: 25265550 [TBL] [Abstract][Full Text] [Related]
18. Efficient delivery of payload into tumor cells in a controlled manner by TAT and thiolytic cleavable PEG co-modified liposomes. Kuai R; Yuan W; Qin Y; Chen H; Tang J; Yuan M; Zhang Z; He Q Mol Pharm; 2010 Oct; 7(5):1816-26. PubMed ID: 20701288 [TBL] [Abstract][Full Text] [Related]
19. Tat peptide and hexadecylphosphocholine introduction into pegylated liposomal doxorubicin: An in vitro and in vivo study on drug cellular delivery, release, biodistribution and antitumor activity. Teymouri M; Badiee A; Golmohammadzadeh S; Sadri K; Akhtari J; Mellat M; Nikpoor AR; Jaafari MR Int J Pharm; 2016 Sep; 511(1):236-244. PubMed ID: 27363937 [TBL] [Abstract][Full Text] [Related]
20. Targeted delivery of transferrin and TAT co-modified liposomes encapsulating both paclitaxel and doxorubicin for melanoma. Yuan M; Qiu Y; Zhang L; Gao H; He Q Drug Deliv; 2016 May; 23(4):1171-83. PubMed ID: 26036724 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]